Takeda/Lilly Actos Liver Tracking Could Concentrate On Rezulin Drop-Outs
Executive Summary
Takeda is considering conducting a liver toxicity study for the type 2 diabetes drug Actos that would enroll patients taken off Rezulin due to liver enzyme elevations.